BerGenBio

CEO Martin Olin steps down

Bergen, Norway, 10 October 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL inhibitors for severe

unmet medical need, announces today that CEO, Martin Olin will be leaving the

company to pursue other opportunities. Martin will remain in his position during

a transition period.

"On behalf of the Board of Directors, I want to thank him for his work and

leadership over the last three years. Martin has since he joined navigated the

company through a strategic transition and established a solid platform for the

further development of bemcentinib. On behalf of the company, I wish him all the

best in his new endeavors", said Anders Tullgren, Chairman of BerGenBio.

The Board of Directors has initiated a succession process and will actively work

with the management to support and review the business requirements.

"I have thoroughly enjoyed my past three years at BerGenBio. It has been a

privilege to lead the company and contribute to developing a medicine that can

potentially be of great importance to a large number of patients. The company

has a very competent team and an exciting time ahead, and I will follow its path

and progress closely," said Martin Olin.

Anders Tullgren

Chairman of the Board of Directors

Contact requests through:

Rune Skeie, CFO, BerGenBio ASA

Jan Lilleby

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit www.bergenbio.com

This information is subject to the disclosure requirements pursuant to Section 5

-12 the Norwegian Securities Trading Act.

AI Terminal